THE UBIQUITIN-PROTEASOME SYSTEM IN CANCER: MECHANISMS, TARGETS AND THERAPEUTIC POTENTIAL
DOI:
https://doi.org/10.15407/exp-oncology.2025.04.395Keywords:
ubiquitin-proteasome system, ubiquitination, ubiquitin-specific proteases, deubiquitinating enzymes, cancer, targeted therapyAbstract
The ubiquitin-proteasome system (UPS) is the central mechanism for regulated intracellular protein degradation in eukaryotic cells, controlling essential biological processes including cell cycle progression, DNA repair, apoptosis, and signal transduction. Through a hierarchical enzymatic cascade, ubiquitin is covalently attached to substrate proteins, often as polyubiquitin chains, marking them for selective degradation by the 26S proteasome. Dysregulation of this system is a hallmark of cancer, where altered ubiquitination dynamics can drive malignant transformation by promoting the degradation of tumor suppressors or stabilizing oncogenic proteins. Deubiquitinating enzymes (DUBs), particularly the ubiquitin-specific protease (USPs) family, reverse ubiquitination and help maintain protein homeostasis. Many USPs are aberrantly expressed or genetically altered in tumors, contributing to oncogenic signaling, resistance to apoptosis, and therapy evasion. This review presents a comprehensive overview of the architecture and function of the UPS, focusing on ubiquitination mechanisms, proteasomal activity, and context-dependent roles of DUBs in cancer. Here, we highlight emerging therapeutic strategies that target various UPS components, including FDA-approved proteasome inhibitors, inhibitors of E3 ligase function, PROTAC-based protein degradation, and small-molecule USP inhibitors. While drugging DUBs remains challenging due to issues of specificity and toxicity, advances in structure-based design and ubiquitin code mapping are accelerating progress. Overall, the UPS is a key regulatory hub in cancer biology and a promising target in precision oncology. Therapeutic modulation of this pathway offers new opportunities for destabilizing oncogenic networks and overcoming resistance mechanisms in cancer.
References
Song L, Luo Z. Post-translational regulation of ubiquitin signaling. J Cell Biol. 2019;218(6):1776-1786. https://doi. org/10.1083/jcb.201902074
Swatek K, Komander D. Ubiquitin modifications. Cell Res. 2016;26(4):399-422. https://doi.org/10.1038/cr.2016.39
Bard J, Goodall E, Greene E, Jonsson E, Dong K, Martin A. Structure and function of the 26S proteasome. Annu Rev Biochem. 2018;87(1):697-724. https://doi.org/10.1146/annurev-biochem-062917-011931
Liu J, Shaik S, Dai X, et al. Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta Rev Cancer. 2015;1855(1):50-60. https://doi.org/10.1016/j.bbcan.2014.11.005
LaPlante G, Zhang W. Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule in- hibitors. Cancers. 2021;13(12):3079. https://doi.org/10.3390/cancers13123079
Poondla N, Chandrasekaran A, Kim K, Ramakrishna S. Deubiquitinating enzymes as cancer biomarkers: new therapeutic opportunities? BMB Rep. 2019;52(3):181-189. https://doi.org/10.5483/bmbrep.2019.52.3.048
Schweitzer A, Aufderheide A, Rudack T, et al. Structure of the human 26S proteasome at a resolution of 3.9 Å. Proc Natl Acad Sci U S A. 2016;113(28):7816-7821. https://doi.org/10.1073/pnas.1608050113
Finley D, Prado M. The proteasome and its network: engineering for adaptability. Cold Spring Harb Perspect Biol. 2019; a033985. https://doi.org/10.1101/cshperspect.a033985
Verma R, Aravind L, Oania R, et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science. 2002;298(5593):611-615. https://doi.org/10.1126/science.1075898
Das T, Song E, Kim E. The multifaceted roles of USP15 in signal transduction. Int J Mol Sci. 2021;22(9):4728. https://doi.org/10.3390/ijms22094728
Liu Y, Dong C, Ren J. Deubiquitination detection of p53 protein in living cells by fluorescence cross-correlation spectroscopy. ACS Omega. 2023;8(39):36588-36596. https://pubs.acs.org/doi/10.1021/acsomega.3c06078
Tsuchida S, Nakayama T. Ubiquitination and deubiquitination in oral disease. Int J Mol Sci. 2021;22(11):5488. https://doi.org/10.3390/ijms22115488
Chen S, Liu Y, Zhou H. Advances in the development of ubiquitin-specific peptidase (USP) inhibitors. Int J Mol Sci. 2021;22(9):4546. https://doi.org/10.3390/ijms22094546
Dantuma N, Bott L. The ubiquitin-proteasome system in neurodegenerative diseases: precipitating factor, yet part of the solution. Front Mol Neurosci. 2014;7:70. https://doi.org/10.3389/fnmol.2014.00070
Park M, Kar R, Banka S, et al. Post-translational formation of hypusine in eIF5A: implications in human neurode- velopment. Amino Acids. 2021;54(4):485-499. https://doi.org/10.1007/s00726-021-03023-6
Han J, Lin L, Fang Z, et al. Cardiomyocyte-derived USP13 protects hearts from hypertrophy via deubiquitinat- ing and stabilizing STAT1 in male mice. Nat Commun. 2025;16(1):5927. https://doi.org/10.1038/s41467-025- 61028-1
Jang HH. Regulation of protein degradation by proteasomes in cancer. J Cancer Prev. 2018;23(4):153-161. https:// doi.org/10.15430/jcp.2018.23.4.153
Huang B, Yang Y, Liu J, et al. Ubiquitination regulation of mitochondrial homeostasis: a new sight for the treatment of gastrointestinal tumors. Front Immunol. 2025;16:1533007. https://doi.org/10.3389/fimmu.2025.1533007
Mazloumi Aboukheili AM, Walden H. USP1 in regulation of DNA repair pathways. DNA Repair (Amst). 2025;146:103807. https://doi.org/10.1016/j.dnarep.2025.103807
Torrado C, Ashton NW, D’Andrea AD, Yap TA. USP1 inhibition: a journey from target discovery to clinical transla- tion. Pharmacol Ther. 2025;271:108865. https://doi.org/10.1016/j.pharmthera.2025.108865
Antonenko S, Gurianov D, Telegeev G. Colocalization of USP1 and РН domain of Bcr-Abl oncoprotein in terms of chronic myeloid leukemia cell rearrangements. Tsitol Genet. 2016;50:11-15. https://doi.org/10.3103/ S0095452716050029
Hu X, Wu Y, Yao M, Chen Z, Li Q. The other side of the coin: protein deubiquitination by Ubiquitin-Specific Pro- tease 1 in cancer progression and therapy. Future Med Chem. 2025;17(3):329-345. https://doi.org/10.1080/175689 19.2025.2453414
Antonenko SV, Telegeev GD. Inhibition of USP1, a new partner of BCR-ABL, results in decrease of Bcr-Abl level in K562 cells. Exp Oncol. 2020;42(2):109-114. https://doi.org/10.32471/exp-oncology.2312-8852.vol-42-no-2.14533
Antonenko S, Gurianov D, Kravchuk I, et al. Role of BCR and FNBP1 proteins in phagocytosis as a model of mem- brane rearrangements with chronic myelogenous leukemia. Cytol Genet. 2023;57:291-297. https://www.doi.org/ https://doi.org/10.3103/S0095452723040023
Antonenko S, Zavelevich M, Telegeev G. The role of USP1 deubiquitinase in the pathogenesis and therapy of can- cer. Acta Biochim Pol. 2023;70(2):219-231. https://doi.org/10.18388/abp.2020_6636
Meng H, Qu Z, Xiao Z, et al. Ubiquitin-specific protease 38 modulates atrial fibrillation susceptibility in chron- ic kidney disease via STRAP stabilization and activation of TGF-/SMAD signaling. Mol Med. 2025;31(1):238. https://doi.org/10.1186/s10020-025-01296-1
Zhiqiang Z, Qinghui Y, Yongqiang Z, et al. USP1 regulates AKT phosphorylation by modulating the stability of PHLPP1 in lung cancer cells. J Cancer Res Clin Oncol. 2012;138:1231-1238. https://doi.org/10.1007/s00432-012-1193-3
Rahme G, Zhang Z, Young A, et al. PDGF engages an E2F-USP1 signaling pathway to support ID2-mediated survival of proneural glioma cells. Cancer Res. 2016;76:2964-2976. https://doi.org/10.1158/0008-5472.can-15-2157
Lee JK, Nam DH, Lee J. Repurposing antipsychotics as glioblastoma therapeutics: potentials and challenges. Oncol Lett. 2016;11:1281-1286. https://doi.org/10.3892/ol.2016.4074
Li JT, Li KY, Su Y, et al. Diet high in branched-chain amino acid promotes PDAC development by USP1-mediated BCAT2 stabilization. Nat Sci Rev. 2022;9:212. https://doi.org/10.1093/nsr/nwab212
Sonego M, Pellarin I, Costa A, et al. USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability. Sci Adv. 2019;5:eaav3235. https://doi.org/10.1126/sciadv.aav3235
Zhang H, Zhang A, Peng P, et al. USP5 facilitates bladder cancer progression by stabilizing the c-Jun protein. Cancer Cell Int. 2024;24(1):32. https://doi.org/10.1186/s12935-024-03222-7
Huang P, Wang Y, Zhang P, Li Q. Ubiquitin-specific peptidase 1: assessing its role in cancer therapy. Clin Exp Med. 2023;23(7):2953-2966. https://doi.org/10.1007/s10238-023-01075-4
He Y, Jiang S, Zhong Y, et al. USP7 promotes non-small-cell lung cancer cell glycolysis and survival by stabilizing and activating c-Abl. Clin Transl Med. 2023;13(12):e1509. https://doi.org/10.1002/ctm2.1509
Sulkshane P, Pawar S, Waghole R, et al. Elevated USP9X drives early-to-late-stage oral tumorigenesis via stabili- sation of anti-apoptotic MCL-1 protein and impacts outcome in oral cancers. Br J Cancer. 2021;125(4):547-560. https://doi.org/10.1038/s41416-021-01421-x
Weisberg E, Schauer N, Yang J, et al. Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017;13(12):1207-1215. https://doi.org/10.1038/nchembio.2486
Yang J, Dai L, Chai J, et al. Narirutin downregulates USP15 to inhibit the NLRP3 ubiquitination in HDM-induced allergic rhinitis. Phytomedicine. 2025;144:156895. https://doi.org/10.1016/j.phymed.2025.156895
Du X, Yu R, Yan C, et al. USP10 promotes the progression and attenuates gemcitabine chemotherapy sensitivity via stabilizing PLK1 in PDAC. Cell Death Dis. 2025;16(1):449. https://doi.org/10.1038/s41419-025-07757-z
Jin Q, Gutierrez Diaz B, Pieters T, et al. Oncogenic deubiquitination controls tyrosine kinase signaling and therapy response in acute lymphoblastic leukemia. Sci Adv. 2022;8(49):eabq8437. https://doi.org/10.1126/sciadv.abq8437
Huangfu L, Zhu H, Wang G, et al. The deubiquitinase USP15 drives malignant progression of gastric cancer through glucose metabolism remodeling. J Exp Clin Cancer Res. 2024;43:235. https://doi.org/10.1186/s13046-024-03152-2
Yang J, Meng C, Weisberg E, et al. Inhibition of the deubiquitinase USP10 induces degradation of SYK. Br J Cancer. 2020;122:1175-1184. https://doi.org/10.1038/s41416-020-0731-z
Chiurillo MA. Role of the Wnt/-catenin pathway in gastric cancer: an in-depth literature review. World J Exp Med. 2015;5(2):84-102. https://doi.org/10.5493/wjem.v5.i2.84
Li Q, Ye C, Tian T, et al. The emerging role of ubiquitin-specific protease 20 in tumorigenesis and cancer therapeu- tics. Cell Death Dis. 2022;13:434. https://doi.org/10.1038/s41419-022-04853-2
Wei Y, Jiang Z, Lu J. USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization. Oncol Lett. 2021;21(5):394. https://doi.org/10.3892/ol.2021.12655
Han F, Qi G, Li R, et al. USP28 promotes PARP inhibitor resistance by enhancing SOX9-mediated DNA damage repair in ovarian cancer. Cell Death Dis. 2025;16:305. https://doi.org/10.1038/s41419-025-07647-4
Collins M, Avery R, Albert F. Substrate-specific effects of natural genetic variation on proteasome activity. PLoS Genet. 2023;19(5):e1010734. https://doi.org/10.1371/journal.pgen.1010734
Oon CE, Anbazhagan P, Tan CT. Therapeutic potential of targeting ubiquitin-specific proteases in colorectal cancer.
Drug Discov Today. 2025;30(5):104356. https://doi.org/10.1016/j.drudis.2025.104356
Gao H, Xi Z, Dai J, et al. Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specif- ic Proteases (USPs) in cancers: new directions and therapeutic options. Mol Cancer. 2024;23(1):88. https://doi. org/10.1186/s12943-024-02005-y
Bakkar M, Khalil S, Bhayekar K, et al. Ubiquitin-specific protease inhibitors for cancer therapy: recent advances and future prospects. Biomolecules. 2025;15(2):240. https://doi.org/10.3390/biom15020240
Chen R, Chen Y, Huang T. Ubiquitin-mediated regulation of autophagy. J Biomed Sci. 2019;26(1). https://doi. org/10.1186/s12929-019-0569-y
Han Z, Jia Q, Zhang J, et al. Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis. J Exp Clin Cancer Res. 2023;42(1). https://doi.org/10.1186/s13046-023-02781-3
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
